Rylaze (crisantaspase recombinant)

pCPA File Number: 22356
Negotiation Status:
Concluded with an LOI
Indication(s):
For the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.
Sponsor/Manufacturer:
Jazz Pharmaceuticals Canada Inc.
CADTH Project Number:
PC0301
pCPA Engagement Letter Issued:
Negotiation Process Concluded: